Baeyens, Ans

Kotzen, Jeffrey

Minnaar, Carrie Anne

English

Ghent University Academic Bibliography

29.3Gy  and  29.6Gy  in  stage  3/4.  Average  rectum  D2cc  was 19.2Gy, 16.5Gy and 19.9Gy in stage 1/2 and 21.8Gy, 24.6Gy  and  26.3Gy  for  stage  3/4.  Average  bladder  D2cc  was  46.2Gy,  27.9Gy,  and  24.4Gy  for  stage  1/2,  and  31.2Gy,  38.1Gy  and  35.8Gy  for  stage  3/4  (table  2).   Conclusion  MR    guided    BT    improves    HRCTV    dose    coverage    dramatically. In our cohort average HRCTV D90 increased by more than 20Gy for stage 1/2 and more than 10GY for stage  3/4  disease.  Improvements  were  also  seen  in  the  OARs; bladder D2cc more than rectal D2cc. The reduction in bladder dose was largest for stage 1/2 disease. The use of needles allowed similar dose coverage despite a large difference  in  the  HRCTV  volume.  The  benefits  of  image  guided  BT  with  interstitial  needles  is  therefore  seen  in  HRCTV  coverage  as  well  as  OAR  dose.  To  achieve  the  EMBRACE2  tolerances,  further  reductions  in  OAR  doses,  especially rectum, are necessary to facilitate an increase in  the  BT  dose  fractionation  to  28Gy  in  4  fractions  with  EBRT dose at 45Gy in 25 fractions. This will improve with experience or perhaps the use of oblique needles to treat side wall disease more effectively.   EP-1531  Hyperthermia (mEHT) as a radiosensitser in HIV positive cervical cancer patients: effects/toxicities C. Minnaar1, A. Baeyens2, J. Kotzen3 1University of the Witwatersrand, Radiobiology, Johannesburg, South Africa 2Ghent University, Basic Medical Sciences, Ghent, Belgium 3University of the Witwatersrand, Radiation Oncology, Johannesburg, South Africa  Purpose or Objective  To   report   on   the   effects   of   modulated   electro-hyperthermia (mEHT) as a radiosensitiser on toxicity and local  disease  control  in  HIV  positive  cervical  cancer  patients.  Material and Methods  136  participants  were  prescribed  50Gy  external  beam  radiation,  3  doses  of  8Gy  high  dose  rate  brachytherapy  and   cisplatin   as   a   radiosensitiser.   Participants   were   randomised,  based  on  HIV  status,  FIGO  stage  of  disease,  and  age,  into  a  control  group  or  study  group.  The  study  group  received  10  mEHT  treatments  plus  the  prescribed  chemoradiotherapy regime. Each mEHT treatment was 55 minutes   at   a   target   power   of   130W.   HIV   positive   participants  must  have  been  on  antiretroviral  treatment  for  a  minimum  of  6  months  and  have  a  CD4  count  of  above     200cells/mm3.     Participants     with     bilateral     hydronephrosis    and    a    creatinine    clearance    below    positive.  Complete  response  (CR)  rates  are  as  follows:  HIV  positive  study:  67%;  HIV  negative  study:  54%;  HIV positive control: 57%; HIV negative control: 37%. 6 month survival in the HIV positive and negative study groups are 89%  and  100%  respectively,  and  in  the  HIV  positive  and  negative  control  groups  survival  was  84%  and  87.5%  respectively.  The  frequency  of  grade  4  toxicities  on  treatment  was  higher  in  the  HIV  positive  groups  compared  to  the  HIV  negative  groups.  However  the  frequency  of  grade  3  toxicities  was  highest  in  the  HIV  negative  control  group.  The  most  common  toxicity  was  bladder.  1  Grade  3  skin  toxicity was reported in both HIV positive groups and 1 in the HIV negative control group.  At  3  months,  skin  and  bladder  toxicity  was  higher  in  the  HIV  positive  study  group  than  the  HIV  negative  study  group,  with  2  grade  4  bladder  toxicities  in  the  HIV  positive  study  group.  The  HIV  negative  control  group  reported  the  highest  frequency  of  bladder  toxicities:  3  grade  3  and  4  grade  4  toxicities.  There  were  no  grade  3  or  4  lower  GI/rectal  toxicities  in  the  study  group  and  2  grade  4  toxicities  in  both  control  groups  (HIV  negative  and positive). Conclusion  Early results do not show an obvious pattern/relationship in the frequency/severity of toxicities in the HIV positive groups compared to the HIV negative groups, irrespective of  the  administration  of  mEHT.  Overall  the  local  disease  control is improved in the study group. There is a higher CR rate in HIV positive groups of each arm. The 6 month survival does not show the same pattern of improvement in the HIV positive groups. Survival at 6 months is higher in  the  study  group.  The  significance  of  this  will  be  confirmed in a larger sample and longer follow up.  EP-1532  HIV and Cervical Cancer, dangerous combination for RT patients H. Pérez Montero1, S. Guardado2, N. Gascón2, V. Rodríguez2, R. D'Ambrosi2, M. Fasano2, L. Asiáin2, J. Pérez-Regadera2 1Institut Català d Óncologia, Radiation Oncology, Barcelona, Spain 2Hospital Universitario 12 de Octubre, Radiation Oncology, Madrid, Spain  Purpose or Objective  The  association  between  cervical  cancer  and  HIV  is  well  known, being one of the defining conditions of AIDS, and one  of  the  most  common  neoplasms  related  to  this  disease. In addition, the evolution of HIV disease and response to treatment seems to be modified in this group of patients, having  the  tumor  a  more  aggressive  behavior  and  worse  prognosis compared to non-HIV population. Objective:   Describe   evolution   of   HIV   patients   with   cervical cancer treated with radiotherapy in our center.   1 / 1 Article info HideRecommended ArticlesNo articles found

Hyperthermia (mEHT) as a radiosensitser in HIV positive cervical cancer patients : effects/toxicities

https://biblio.ugent.be/publication/8660570/file/8660571

Hyperthermia (mEHT) as a radiosensitser in HIV positive cervical cancer patients : effects/toxicities

Abstract

Similar works

Full text

Available Versions

Ghent University Academic Bibliography